3.61
2.43%
-0.09
Atea Pharmaceuticals Inc stock is currently priced at $3.61, with a 24-hour trading volume of 263.54K.
It has seen a -2.43% decreased in the last 24 hours and a -8.84% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.75 pivot point. If it approaches the $3.59 support level, significant changes may occur.
Previous Close:
$3.70
Open:
$3.7
24h Volume:
263.54K
Market Cap:
$304.05M
Revenue:
$351.37M
Net Income/Loss:
$-135.96M
P/E Ratio:
-2.8203
EPS:
-1.28
Net Cash Flow:
$-85.40M
1W Performance:
-2.43%
1M Performance:
-8.84%
6M Performance:
+21.14%
1Y Performance:
-11.74%
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Name
Atea Pharmaceuticals Inc
Sector
Industry
Phone
857 284 8891
Address
125 Summer Street, Boston
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight |
Jan-06-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Nov-18-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Nov-25-20 | Initiated | Evercore ISI | Outperform |
Nov-24-20 | Initiated | JP Morgan | Overweight |
Nov-24-20 | Initiated | Morgan Stanley | Overweight |
Nov-24-20 | Initiated | William Blair | Outperform |
View All
Atea Pharmaceuticals Inc Stock (AVIR) Latest News
Atea (AVIR) Dengue Candidate Gets Fast Track Designation - Yahoo Movies UK
Yahoo Movies UK
Recent Insider Activity Could Benefit Atea Pharmaceuticals Inc (AVIR) – Knox Daily - Knox Daily
Knox Daily
Top investors say Atea Pharmaceuticals Inc (AVIR) ticks everything they need – Sete News - SETE News
SETE News
Atea pharmaceuticals CEO sells shares worth $4,024 By Investing.com - Investing.com Australia
Investing.com Australia
Atea pharmaceuticals CEO sells shares worth $4024 - Investing.com India
Investing.com India
Atea Pharmaceuticals (NASDAQ:AVIR) shareholders have endured a 68% loss from investing in the stock a year ago - Yahoo News Australia
Yahoo News Australia
Atea Pharmaceuticals Inc Stock (AVIR) Financials Data
Atea Pharmaceuticals Inc (AVIR) Revenue 2024
AVIR reported a revenue (TTM) of $351.37 million for the quarter ending December 31, 2021.
Atea Pharmaceuticals Inc (AVIR) Net Income 2024
AVIR net income (TTM) was -$135.96 million for the quarter ending December 31, 2023, a -17.30% decrease year-over-year.
Atea Pharmaceuticals Inc (AVIR) Cash Flow 2024
AVIR recorded a free cash flow (TTM) of -$85.39 million for the quarter ending December 31, 2023, a +30.53% increase year-over-year.
Atea Pharmaceuticals Inc (AVIR) Earnings per Share 2024
AVIR earnings per share (TTM) was -$1.64 for the quarter ending December 31, 2023, a -17.14% decline year-over-year.
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. The company's lead product candidate is AT-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2. It also develops AT-787 for the treatment of hepatitis C virus; AT-752 for the treatment of dengue; AT-889, AT-934, and other product candidates for the treatment of respiratory syncytial virus. The company was incorporated in 2012 and is based in Boston, Massachusetts.
Cap:
|
Volume (24h):